Skip to content

Venticute in Patients With Pneumonia or Aspiration of Gastric Contents and Intubation/Ventilation/Oxygenation Impairment (BY2001/M1-007)

Venticute in Patients With Pneumonia or Aspiration of Gastric Contents Leading to Intubation, Ventilation, and Severe Oxygenation Impairment: A Randomized, Multinational, Multicenter, Parallel Group, Double Blind, Control Group Study

Status
Completed
Phases
Phase 3
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT00074906
Enrollment
1200
Registered
2003-12-25
Start date
2003-11-30
Completion date
2008-06-30
Last updated
2012-05-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pneumonia

Keywords

Aspiration of gastric contents

Brief summary

Study to demonstrate that administration of Venticute increases survival of patients with pneumonia or aspiration of gastric contents leading to intubation, mechanical ventilation, and severe oxygenation impairment.

Interventions

DRUGVenticute

Patients With Pneumonia or Aspiration of Gastric Contents and Intubation/Ventilation/Oxygenation Impairment

Sponsors

Takeda
Lead SponsorINDUSTRY

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
TRIPLE (Subject, Caregiver, Investigator)

Eligibility

Sex/Gender
ALL
Age
12 Years to 85 Years
Healthy volunteers
No

Inclusion criteria

Main inclusion criteria: * Patient has been intubated due to one of the following primary pulmonary insults: aspiration of gastric contents or pneumonia Main

Exclusion criteria

* Principal source of infection or sepsis is outside the lung * Severe pre-existing lung disease * Cancer metastatic to the lung or any end stage malignancy * History of lung, liver, pancreas, small bowel, or bone marrow/stem cell transplantation * Patient is morbidly obese * Patient has a diagnosis of acute necrotizing pancreatitis Additional criteria may apply and examination by an investigator is required to determine eligibility.

Design outcomes

Primary

MeasureTime frame
Survival on day 2828 days

Secondary

MeasureTime frame
How long the lung and the patient (overall) are recovering28 days

Countries

Australia, Austria, Belgium, Denmark, Estonia, Finland, Germany, Greece, Hungary, Israel, Netherlands, New Zealand, Russia, South Africa, Spain, Switzerland, United Kingdom

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026